{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:31:39Z","timestamp":1789421499929,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T00:00:00Z","timestamp":1250640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s10620-009-0933-y","type":"journal-article","created":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T16:33:01Z","timestamp":1250613181000},"page":"1770-1777","source":"Crossref","is-referenced-by-count":39,"title":["JAK2V617F Mutation in Patients with Splanchnic Vein Thrombosis"],"prefix":"10.1007","volume":"55","author":[{"given":"Sandra Guerra","family":"Xavier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telma","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glic\u00ednia","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Maria","family":"Eugenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Dias","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Mendes","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bonamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana Renault","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,19]]},"reference":[{"key":"933_CR1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224\u20132232.","journal-title":"J Clin Oncol"},{"key":"933_CR2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF01725198","volume":"67","author":"BR Anger","year":"1989","unstructured":"Anger BR, Seifried E, Scheppach J, Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr. 1989;67:818\u2013825.","journal-title":"Klin Wochenschr"},{"key":"933_CR3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s002770050555","volume":"78","author":"M Bazzan","year":"1999","unstructured":"Bazzan M, Tamponi G, Schinco P, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999;78:539\u2013543.","journal-title":"Ann Hematol"},{"key":"933_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep.510310307","volume":"31","author":"MH Denninger","year":"2000","unstructured":"Denninger MH, Cha\u00eft Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587\u2013591.","journal-title":"Hepatology"},{"key":"933_CR5","first-page":"2364","volume":"96","author":"HLA Janssen","year":"2000","unstructured":"Janssen HLA, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364\u20132368.","journal-title":"Blood"},{"key":"933_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2002-23202","volume":"22","author":"D Valla","year":"2002","unstructured":"Valla D. Hepatic vein thrombosis (Budd-Chiari Syndrome). Semin Liver Dis. 2002;22:5\u201314.","journal-title":"Semin Liver Dis"},{"key":"933_CR7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/hep.20591","volume":"41","author":"M Primignani","year":"2005","unstructured":"Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41:603\u2013608.","journal-title":"Hepatology"},{"key":"933_CR8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","volume":"129","author":"Y Chait","year":"2005","unstructured":"Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129:553\u2013560.","journal-title":"Br J Haematol"},{"key":"933_CR9","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","volume":"100","author":"JL Spivak","year":"2002","unstructured":"Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272\u20134290.","journal-title":"Blood"},{"key":"933_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0609.2006.00667.x","volume":"77","author":"PJ Thurmes","year":"2006","unstructured":"Thurmes PJ, Steensma DP. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Eur J Haematol. 2006;77:57\u201360.","journal-title":"Eur J Haematol"},{"key":"933_CR11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u20131061.","journal-title":"Lancet"},{"key":"933_CR12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le-Cou\u00e9dic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20131148.","journal-title":"Nature"},{"key":"933_CR13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell. 2005;7:387\u2013397.","journal-title":"Cancer Cell"},{"key":"933_CR14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u20131790.","journal-title":"N Engl J Med"},{"key":"933_CR15","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","volume":"107","author":"AI Schafer","year":"2006","unstructured":"Schafer AI. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood. 2006;107:4214\u20134222.","journal-title":"Blood"},{"key":"933_CR16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humpath.2008.02.004","volume":"39","author":"CA Smith","year":"2008","unstructured":"Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol. 2008;39:795\u2013810.","journal-title":"Hum Pathol"},{"key":"933_CR17","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","volume":"5","author":"V Stefano De","year":"2007","unstructured":"De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708\u2013714.","journal-title":"J Thromb Haemost"},{"key":"933_CR18","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","volume":"130","author":"RK Patel","year":"2006","unstructured":"Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031\u20132038.","journal-title":"Gastroenterology"},{"key":"933_CR19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/hep.21435","volume":"44","author":"M Primignani","year":"2006","unstructured":"Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528\u20131534.","journal-title":"Hepatology"},{"key":"933_CR20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1751-553X.2007.00973.x","volume":"30","author":"C Goulding","year":"2008","unstructured":"Goulding C, Uttenthal B, Foroni L, et al. The JAK2 V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Haematol. 2008;30:415\u2013419.","journal-title":"Int J Lab Haematol"},{"key":"933_CR21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1538-7836.2007.02384.x","volume":"5","author":"S Regina","year":"2007","unstructured":"Regina S, Herault O, D\u2019Alteroche L, Binet C, Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost. 2007;5:859\u2013861.","journal-title":"J Thromb Haemost"},{"key":"933_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3324\/haematol.10358","volume":"92","author":"AF Remacha","year":"2007","unstructured":"Remacha AF, Estivill C, Sarda MP, et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica. 2007;92:285\u2013286.","journal-title":"Haematologica"},{"key":"933_CR23","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1538-7836.2007.02616.x","volume":"5","author":"A Pardanani","year":"2007","unstructured":"Pardanani A, Lasho TL, Morice WG, Pruthi RK, Tefferi A. JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder. J Thromb Haemost. 2007;5:1784\u20131785.","journal-title":"J Thromb Haemost"},{"key":"933_CR24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/jmg.2006.048371","volume":"44","author":"D Colaizzo","year":"2007","unstructured":"Colaizzo D, Amitrano L, Iannaccone L, et al. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. J Med Genet. 2007;44:412\u2013416.","journal-title":"J Med Genet"},{"key":"933_CR25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4065\/83.4.457","volume":"83","author":"A Pardanani","year":"2008","unstructured":"Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008;83:457\u2013459.","journal-title":"Mayo Clin Proc"},{"key":"933_CR26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MBC.0b013e328304e0a9","volume":"19","author":"SG Xavier","year":"2008","unstructured":"Xavier SG, Gadelha T, Schaffel R, et al. Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis. Blood Coagul Fibrinolysis. 2008;19:468\u2013469.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"933_CR27","series-title":"World Health Organization Classification of Tumours","first-page":"32","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"R Pierre","year":"2001","unstructured":"Pierre R, Imbert M, Thiele J, et al. WHO classification of the chronic myeloproliferative diseases (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours, vol. 3. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32\u201344."},{"key":"933_CR28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092\u20131097.","journal-title":"Blood"},{"key":"933_CR29","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/nar\/17.7.2503","volume":"17","author":"CR Newton","year":"1989","unstructured":"Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17:2503\u20132516.","journal-title":"Nucleic Acids Res"},{"key":"933_CR30","unstructured":"Bonamino M, Gomes F, Guimar\u00e3es-Sternberg C, et al. Qualitative and Quantitative Analysis of JAK2V617F Mutations Unravels Higher Responsiveness of JAK2\u00a0+\u00a0ET Patients Treated with Hydroxyurea. 14th Congress of the EHA, 2009, abstract 1790 (ahead of print)."},{"key":"933_CR31","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"AV Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162\u20132168.","journal-title":"Blood"},{"key":"933_CR32","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","volume":"353","author":"FR Rosendaal","year":"1999","unstructured":"Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167\u20131173.","journal-title":"Lancet"},{"key":"933_CR33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-0028-1085097","volume":"28","author":"M Primignani","year":"2008","unstructured":"Primignani M, Mannucci PM. The role of thrombophilia in splanchnic vein thrombosis. Semin Liver Dis. 2008;28:293\u2013301.","journal-title":"Semin Liver Dis"},{"key":"933_CR34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","volume":"23","author":"V Stefano De","year":"1997","unstructured":"De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411\u2013418.","journal-title":"Semin Thromb Hemost"},{"key":"933_CR35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11739-008-0128-0","volume":"3","author":"FL Fimognari","year":"2008","unstructured":"Fimognari FL, Violi F. Portal vein thrombosis in liver cirrhosis. Intern Emerg Med. 2008;3:213\u2013218.","journal-title":"Intern Emerg Med"},{"key":"933_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1538-7836.2006.02277.x","volume":"5","author":"D Colaizzo","year":"2007","unstructured":"Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55\u201361.","journal-title":"J Thromb Haemost"},{"key":"933_CR37","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","volume":"11","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cervantes F, Leebeek FWG, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;11:4922\u20134929.","journal-title":"Blood"},{"key":"933_CR38","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1007\/s10620-008-0225-y","volume":"53","author":"Y Bayraktar","year":"2008","unstructured":"Bayraktar Y, Harmanci O, B\u00fcy\u00fckasik Y, et al. JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci. 2008;53:2778\u20132783.","journal-title":"Dig Dis Sci"},{"key":"933_CR39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2008.253","volume":"22","author":"R Landolfi","year":"2008","unstructured":"Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020\u20132028.","journal-title":"Leukemia"},{"key":"933_CR40","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","volume":"113","author":"S Sozer","year":"2009","unstructured":"Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113:5246\u20135249.","journal-title":"Blood"},{"key":"933_CR41","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","volume":"355","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452\u20132466.","journal-title":"N Engl J Med"},{"key":"933_CR42","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110:4030\u20134036.","journal-title":"Blood"},{"key":"933_CR43","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299\u20131307.","journal-title":"Leukemia"},{"key":"933_CR44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1309\/JA1WD8JNVLGYNQYE","volume":"127","author":"C McMahon","year":"2007","unstructured":"McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol. 2007;127:736\u2013743.","journal-title":"Am J Clin Pathol"},{"key":"933_CR45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.21601","volume":"45","author":"V Stefano De","year":"2007","unstructured":"De Stefano V, Fiorini A, Rossi E, et al. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. Hepatology. 2007;45:831\u2013832.","journal-title":"Hepatology"},{"key":"933_CR46","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2006-05-021527","volume":"108","author":"M Boissinot","year":"2006","unstructured":"Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2\u2013V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood. 2006;108:3223\u20133224.","journal-title":"Blood"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0933-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-009-0933-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-009-0933-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:42:51Z","timestamp":1559230971000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-009-0933-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,19]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s10620-009-0933-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,19]]}}}